Literature DB >> 23680885

Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.

Abdullah Pandor1, Tim Gomersall, John W Stevens, Jenny Wang, Abdallah Al-Mohammad, Ameet Bakhai, John G F Cleland, Martin R Cowie, Ruth Wong.   

Abstract

CONTEXT: Readmission to hospital for heart failure is common after recent discharge. Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.
OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure. STUDY
DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles. STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included. RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM). DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.
RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM). No trial of implanted monitoring devices met the inclusion criteria. Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18). Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant. No beneficial effect on mortality was observed with STS HM. Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions. Care packages generally improved health-related quality-of-life and were acceptable to patients.
CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure. Where 'usual' care is less good, the impact of RM is likely to be greater.

Entities:  

Keywords:  EBM; HEART FAILURE

Mesh:

Year:  2013        PMID: 23680885     DOI: 10.1136/heartjnl-2013-303811

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  42 in total

1.  HerzMobil Tirol network: rationale for and design of a collaborative heart failure disease management program in Austria.

Authors:  Andreas Von der Heidt; Elske Ammenwerth; Karl Bauer; Bettina Fetz; Thomas Fluckinger; Andrea Gassner; Willhelm Grander; Walter Gritsch; Immaculata Haffner; Gudrun Henle-Talirz; Stefan Hoschek; Stephan Huter; Peter Kastner; Susanne Krestan; Peter Kufner; Robert Modre-Osprian; Josef Noebl; Momen Radi; Clemens Raffeiner; Stefan Welte; Andreas Wiseman; Gerhard Poelzl
Journal:  Wien Klin Wochenschr       Date:  2014-11-13       Impact factor: 1.704

Review 2.  Transforming health care delivery through consumer engagement, health data transparency, and patient-generated health information.

Authors:  D Z Sands; J S Wald
Journal:  Yearb Med Inform       Date:  2014-08-15

Review 3.  Technology-assisted congestive heart failure care.

Authors:  P Iyngkaran; S R Toukhsati; N Biddagardi; H Zimmet; J J Atherton; D L Hare
Journal:  Curr Heart Fail Rep       Date:  2015-04

Review 4.  Remote monitoring of implantable cardiac devices in heart failure patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Sultan Alotaibi; Jaime Hernandez-Montfort; Omar E Ali; Karim El-Chilali; Bernardo A Perez
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

5.  Statistical Process Control Improves The Feasibility Of Remote Physiological Monitoring In Patients With Chronic Obstructive Pulmonary Disease.

Authors:  Christopher B Cooper; Worawan Sirichana; Eric V Neufeld; Michael Taylor; Xiaoyan Wang; Brett A Dolezal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-13

6.  The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF).

Authors:  Norihiko Kotooka; Masafumi Kitakaze; Kengo Nagashima; Machiko Asaka; Yoshiharu Kinugasa; Kotaro Nochioka; Atsushi Mizuno; Daisuke Nagatomo; Daigo Mine; Yoko Yamada; Akiko Kuratomi; Norihiro Okada; Daisuke Fujimatsu; So Kuwahata; Shigeru Toyoda; Shin-Ichi Hirotani; Takahiro Komori; Kazuo Eguchi; Kazuomi Kario; Takayuki Inomata; Kaoru Sugi; Kazuhiro Yamamoto; Hiroyuki Tsutsui; Tohru Masuyama; Hiroaki Shimokawa; Shin-Ichi Momomura; Yoshihiko Seino; Yasunori Sato; Teruo Inoue; Koichi Node
Journal:  Heart Vessels       Date:  2018-02-15       Impact factor: 2.037

7.  Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.

Authors:  Jordana K Schmier; Kevin L Ong; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2017-03-08       Impact factor: 2.882

8.  Telemedical Care and Monitoring for Patients with Chronic Heart Failure Has a Positive Effect on Survival.

Authors:  Robert Herold; Neeltje van den Berg; Marcus Dörr; Wolfgang Hoffmann
Journal:  Health Serv Res       Date:  2017-01-31       Impact factor: 3.402

9.  Guideline of the Brazilian Society of Cardiology on Telemedicine in Cardiology - 2019.

Authors:  Marcelo Antônio Cartaxo Queiroga Lopes; Gláucia Maria Moraes de Oliveira; Antonio Luiz Pinho Ribeiro; Fausto J Pinto; Helena Cramer Veiga Rey; Leandro Ioschpe Zimerman; Carlos Eduardo Rochitte; Fernando Bacal; Carisi Anne Polanczyk; Cidio Halperin; Edson Correia Araújo; Evandro Tinoco Mesquita; José Airton Arruda; Luis Eduardo Paim Rohde; Max Grinberg; Miguel Moretti; Paulo Ricardo Avancini Caramori; Roberto Vieira Botelho; Andréa Araújo Brandão; Ludhmila Abrahão Hajjar; Alexandre Fonseca Santos; Alexandre Siciliano Colafranceschi; Ana Paula Beck da Silva Etges; Bárbara Campos Abreu Marino; Bruna Stella Zanotto; Bruno Ramos Nascimento; Cesar Rocha Medeiros; Daniel Vitor de Vasconcelos Santos; Daniela Matos Arrowsmith Cook; Eduardo Antoniolli; Erito Marques de Souza Filho; Fábio Fernandes; Fabio Gandour; Francisco Fernandez; Germano Emilio Conceição Souza; Guilherme de Souza Weigert; Iran Castro; Jamil Ribeiro Cade; José Albuquerque de Figueiredo Neto; Juliano de Lara Fernandes; Marcelo Souza Hadlich; Marco Antonio Praça Oliveira; Maria Beatriz Alkmim; Maria Cristina da Paixão; Maurício Lopes Prudente; Miguel A S Aguiar Netto; Milena Soriano Marcolino; Monica Amorim de Oliveira; Osvaldo Simonelli; Pedro A Lemos Neto; Priscila Raupp da Rosa; Renato Minelli Figueira; Roberto Caldeira Cury; Rodrigo Coelho Almeida; Sandra Regina Franco Lima; Silvio Henrique Barberato; Thiago Inocêncio Constancio; Wladimir Fernandes de Rezende
Journal:  Arq Bras Cardiol       Date:  2019-11       Impact factor: 2.000

10.  Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial.

Authors:  Michael K Ong; Patrick S Romano; Sarah Edgington; Harriet U Aronow; Andrew D Auerbach; Jeanne T Black; Teresa De Marco; Jose J Escarce; Lorraine S Evangelista; Barbara Hanna; Theodore G Ganiats; Barry H Greenberg; Sheldon Greenfield; Sherrie H Kaplan; Asher Kimchi; Honghu Liu; Dawn Lombardo; Carol M Mangione; Bahman Sadeghi; Banafsheh Sadeghi; Majid Sarrafzadeh; Kathleen Tong; Gregg C Fonarow
Journal:  JAMA Intern Med       Date:  2016-03       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.